EpiCept gains on EpiCept-NP1 data

EpiCept Corp. (NASDAQ:EPCT; SSE:EPCT) gained $0.10 (13%) to $0.85 on Monday after the company said EpiCept NP-1 met the primary endpoint in a Phase IIb trial to treat chemotherapy-induced peripheral n...